Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Safety Study of Nivolumab in Patients With Recurrent and/or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)

NCT03226756 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT03226756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03226756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Safety Study of Nivolumab in Patients With Recurrent and/or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Completed
Start date
July 7, 2017
Completion date
May 31, 2022
Enrollment
351 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent and/or metastatic platinum-refractory scchn